New
Why Viking Therapeutics Stock Plummeted By 24% In December
Viking Therapeutics (NASDAQ: VKTX) didn't exactly capture investors' hearts in the final month of 2024. The biotech company's share price eroded by 24% in December, primarily on the back of a rival's aggressive move into a potentially very lucrative segment of the pharmaceutical market.
Intensifying competition
That rival is a large and determined one: global pharmaceutical incumbent Merck (NYSE: MRK).
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. See the 10 stocks »
In mid-December, Merck announced it had entered into a licensing deal with China-based biotech Hansoh Pharma for that company's investigational weight-loss drug. If developed successfully, the drug, labeled HS-10535, would surely pose a serious threat to Viking's No. 1 pipeline program, VK2735. This, too, is an obesity drug; it has tested well in clinical trials and is relatively advanced in its development process.
It is also an orally administered treatment, giving it an advantage over competing products on the American market that are already Food and Drug Administration (FDA)-approved for the disorder. These are Novo Nordisk's Wegovy and Eli Lilly's Zepbound, both of which are delivered via injection.
Merck's arrangement with Hansoh gives the former company exclusive global licensing rights to HS-10535, which is currently in development. Merck has already committed quite significantly to this, signing on to a $112 million up-front payment in the deal. The company has also agreed to pay its Chinese partner as much as $1.9 billion in milestone payments and royalties, assuming, of course, that the drug is ultimately brought to market.
The stakes are high in the weight-loss game. With only two GLP-1 drugs approved specifically for weight loss in the U.S., the market is still wide open. Meanwhile, such drugs are enjoying white-hot popularity in a country notable for its high rates of obesity. Americans love the idea of being able to jettison diet and exercise regimes in favor of simply taking a drug to shed pounds. So, demand is currently very strong and should remain so.
A Viking shouldn't surrender
While Viking investors are right to be concerned with Merck's move -- the company is large, powerful, and obviously has a plan -- I wouldn't be ready to throw in the towel just yet. HS-10535 still has some distance to go in its development cycle, and there's no telling how efficacious it'll ultimately prove to be.
VK2735, then, seems like a better bet to make it to the hallowed commercialization stage. Given that it's an oral treatment rather than an injectible, it's sure to be a go-to treatment from the jump.
Should you invest $1,000 in Viking Therapeutics right now?
Before you buy stock in Viking Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Viking Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $885,388!*
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.
*Stock Advisor returns as of December 30, 2024
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Merck. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy.
